

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

**UNAUDITED FINANCIAL INFORMATION OF
CSPC INNOVATION PHARMACEUTICAL CO., LTD.
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024**

In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”), a subsidiary of CSPC Pharmaceutical Group Limited (the “**Company**”) listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765), has on 23 October 2024 published its unaudited third quarterly report for the nine months ended 30 September 2024 (the “**2024 Third Quarterly Report**”) on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>. CSPC Innovation’s financial information was prepared in accordance with the China Accounting Standards for Business Enterprises.

Set out in the appendices to this announcement (the “**Appendices**”) is the principal financial data of CSPC Innovation extracted from the 2024 Third Quarterly Report in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

Shareholders and investors are reminded that the financial information of CSPC Innovation in the 2024 Third Quarterly Report and in the Appendices are unaudited consolidated financial information of CSPC Innovation for the nine months ended 30 September 2024, rather than that of the Company. Investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 23 October 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

APPENDIX I

KEY ACCOUNTING INFORMATION AND FINANCIAL INDICATORS

Unit: RMB (Yuan)

	Current reporting period	Corresponding period of the last year		Increase/decrease of the current reporting period compared to the corresponding period of the last year	From the beginning of the year to the end of the reporting period	Corresponding period of the last year		Increase/decrease from the beginning of the year to the end of the reporting period compared to the corresponding period of the last year
		Before adjustment	After adjustment			After adjustment	Before adjustment	
Revenue (Yuan)	507,062,812.09	592,260,993.99	592,894,989.81	-14.48%	1,478,923,011.81	1,901,871,567.32	1,937,205,663.14	-23.66%
Net profit attributable to shareholders of the listed company (Yuan)	2,301,889.23	182,858,095.52	116,858,896.66	-98.03%	139,329,413.32	583,476,209.49	381,755,724.89	-63.50%
Net profits attributable to shareholders of the listed company, net of non-recurring gains/losses (Yuan)	2,260,196.27	181,849,227.37	181,849,227.37	-98.76%	136,742,338.33	575,890,836.16	575,890,836.16	-76.26%
Net cash flows generated from operating activities (Yuan)	-	-	-	-	-955,575,497.94	676,946,034.19	-6,993,628.68	-13,563.51%
Basic earnings per share (Yuan/share)	0.0020	0.1562	0.0838	-97.61%	0.0995	0.5066	0.2738	-63.66%
Diluted earnings per share (Yuan/share)	0.0020	0.1562	0.0838	-97.61%	0.0995	0.5066	0.2738	-63.66%
Weighted average return on net assets (%)	0.06%	3.79%	2.55%	-2.49%	2.82%	12.82%	8.33%	-5.51%
	At the end of the current reporting period	At the end of the last year		Increase/decrease at the end of the current reporting period compared with the end of the last year				
		Before adjustment	After adjustment	After adjustment	After adjustment			
Total assets (Yuan)	5,718,366,517.96	5,632,123,851.51	7,472,208,452.03	-23.47%				
Equity attributable to shareholders of the listed company (Yuan)	3,813,361,674.95	5,078,808,635.08	5,280,823,722.20	-27.79%				

APPENDIX II

NON-RECURRING PROFIT OR LOSS ITEMS AND AMOUNTS

Unit: RMB (Yuan)

Item	Amount for the current reporting period	Amount for the period from the beginning of the year to the end of the reporting period	Description
Gains/losses on disposal of non-current assets (including the portion offset with the provision for impairment of asset)	-358,478.24	-504,922.47	
Government grants recognised in profit or loss for the current period (excluding those closely related to the company's normal business operations, complied with national policies, granted according to established standards, and continuously affecting the Company's profit or loss)	2,189,955.94	5,891,077.66	
Non-operating income and expenses other than the items above	-305,026.27	-168,177.66	
Less: Impact of income tax	991,527.28	1,097,019.21	
Impact on minority interests (after tax)	493,231.19	1,533,883.33	
Total	41,692.96	2,587,074.99	—

APPENDIX III

SIGNIFICANT CHANGES IN ASSETS COMPONENTS

Unit: RMB (Yuan)

Items	30 September 2024	1 January 2024	Changes	Reasons for changes
Cash and bank balances	1,293,549,938.90	3,770,190,307.96	-65.69%	Mainly due to purchase of large-amount deposits, share buy-backs, cash dividends distributions of the company and the settlement of R&D expenses by Megalith
Trade receivables financing	49,351,175.13	84,562,304.15	-41.64%	Mainly due to the decrease in bills receivables of the company
Prepayment	73,527,966.90	37,546,785.82	95.83%	Mainly due to the increase in R&D expenses and construction payable of Megalith
Other current assets	86,876,355.86	22,742,602.54	282.00%	Mainly due to the increase in input tax available for deduction of the company
Construction in progress	421,600,985.38	228,712,565.18	84.34%	Mainly due to the increase in construction projects investment of the company
Other non-current assets	383,409,494.32	26,330,271.98	1,356.15%	Mainly due to the purchase of large-amount deposits by the company
Trade payables	332,174,052.63	1,264,417,016.17	-73.73%	Mainly due to settlement of outstanding R&D expenses of Megalith for the historical period